{"entity":{"id":"her2","kind":"target","name":"HER2","aka":[],"tldr":"A growth-signal receptor. Some cancers make far too much of it, and drugs that block it or use it as a docking site have transformed those cancers.","summary":"Human epidermal growth factor receptor 2 is a receptor tyrosine kinase amplified in ~15-20% of breast cancers and a subset of gastric, colorectal, lung (mutations), and biliary cancers. Trastuzumab (1998) was the first targeted antibody in solid tumours. Trastuzumab deruxtecan redefined the target by working in 'HER2-low' tumours that older drugs ignored, and in 2026 gained approval in early-stage disease.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/HER2/neu","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/HER2/neu"}],"tags":["adc-target","driver"],"related":[],"indications":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["precirix"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06369831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"ERBB2","hgnc":"HGNC:3430","ensembl":"ENSG00000141736","uniprot":"P04626","entrez":"2064","biology":"Ligand-less receptor that heterodimerises with HER3/EGFR to drive PI3K and MAPK signalling. Amplification is a true oncogenic driver; low expression is merely a delivery address for ADCs.","whereFound":["HER2+ breast cancer (~15-20%)","HER2-low breast cancer (~50%)","Gastric/GEJ (~15-20%)","HER2-mutant NSCLC (~2-3%)","Colorectal (~3-5%)","Biliary tract"],"targetClass":"surface-antigen","prevalence":[{"indicationId":"breast-her2-positive","pct":100,"measure":"IHC 3+ or ISH-amplified (defining)","source":"https://www.nature.com/articles/s41591-025-03981-4"}]},"route":"/targets/her2/","neighbours":{"indication":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/"},{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/"}],"company":[{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/"}],"trial":[{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/"}],"technology":[{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/"},{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"term":[{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/"}],"idea":[{"id":"idea-alpha-after-adc","kind":"idea","name":"Alpha radioligands after ADC failure","route":"/ideas/idea-alpha-after-adc/"},{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/"}],"person":[{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/"}],"isotope":[{"id":"th-227","kind":"isotope","name":"Thorium-227","route":"/isotopes/th-227/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/"},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/"}]}}